Johnson and Johnson’s COVID-19 vaccine rollout is scheduled to resume in the US, following the US Centers for Disease Control and Prevention and the Food and Drug Administration recommending to lift the temporary pause on the jab.
The pause was originally recommended following six reported cases in the US of cerebral venous sinus thrombosis (CVST). The rare blood clots were seen in combination with low levels of thrombocytopenia. Almost every report of these events was witnessed in women younger than fifty years old.
“Johnson and Johnson’s COVID-19 vaccine rollout is scheduled to resume in the US.“
Janet Woodcock, acting FDA commissioner, stated: “We have concluded that the known and potential benefits of the COVID-19 vaccine outweigh its known and potential risks in individuals eighteen years of age and older. We are confident that this vaccine continues to meet our standards for safety, effectiveness and quality. We recommend people with questions about which vaccine is right for them have those discussions with their health care provider.”
Chief Scientific Officer, J&J, Paul Stoffels, stated: “As the global pandemic continues to devastate communities around the world, we believe a single-shot, easily transportable COVID-19 vaccine with demonstrated protection against multiple variants can help protect the health and safety of people everywhere.”